TY - JOUR
T1 - Differential expression of somatostatin receptors 1-5 in neuroendocrine carcinoma of the lung
AU - Tsuta, Koji
AU - Wistuba, Ignacio I.
AU - Moran, Cesar A.
N1 - Funding Information:
This work was supported in part by a grant from the U.S. Department of Defense PROSPECT W81XWH-07-1-0306 .
PY - 2012/8/15
Y1 - 2012/8/15
N2 - The majority of neuroendocrine carcinomas (NECs) express somatostatin (SST) receptors (SSTRs). However, the expression of all 5 SSTR subtypes in pulmonary NECs has not been reported. We performed immunohistochemical analysis of all 5 SSTR subtypes (including the SSTR2A and 2B isoforms). In typical carcinoids, immunoexpression of SSTR 1, 2A, 2B, 3, 4, and 5 was observed in 47/56 (79.7%), 57/58 (96.6%), 39/59 (66.1%), 28/57 (49.1%), 3/58 (5.2%), and 0/57 cases, respectively. In atypical carcinoids, immunoexpression of SSTR 1, 2A, 2B, 3, 4, and 5 was observed in 7/9 (77.8%), 7/9 (77.8%), 7/9 (77.8%), 3/9 (33.3%), 0/9, and 0/9 cases, respectively. In large cell NECs, immunoexpression of SSTR types 1, 2A, 2B, 3, 4, and 5 was observed in 12/20 (60%), 12/20 (60%), 6/20 (30%), 8/20 (40%), 0/20, and 3/20 (15%) cases, respectively. In small-cell carcinomas, immunoexpression of SSTR types 1, 2A, 2B, 3, 4, and 5 was observed in 16/54 (27.6%), 40/56 (69%), 14/56 (24.1%), 9/56 (15.5%), 0/58, and 2/55 (3.4%) cases, respectively. Except for SSTR5, all SSTRs showed a tendency toward decreased expression in well- to poorly differentiated NECs. We believe that these findings indicate important implications for the future of SST analog therapy.
AB - The majority of neuroendocrine carcinomas (NECs) express somatostatin (SST) receptors (SSTRs). However, the expression of all 5 SSTR subtypes in pulmonary NECs has not been reported. We performed immunohistochemical analysis of all 5 SSTR subtypes (including the SSTR2A and 2B isoforms). In typical carcinoids, immunoexpression of SSTR 1, 2A, 2B, 3, 4, and 5 was observed in 47/56 (79.7%), 57/58 (96.6%), 39/59 (66.1%), 28/57 (49.1%), 3/58 (5.2%), and 0/57 cases, respectively. In atypical carcinoids, immunoexpression of SSTR 1, 2A, 2B, 3, 4, and 5 was observed in 7/9 (77.8%), 7/9 (77.8%), 7/9 (77.8%), 3/9 (33.3%), 0/9, and 0/9 cases, respectively. In large cell NECs, immunoexpression of SSTR types 1, 2A, 2B, 3, 4, and 5 was observed in 12/20 (60%), 12/20 (60%), 6/20 (30%), 8/20 (40%), 0/20, and 3/20 (15%) cases, respectively. In small-cell carcinomas, immunoexpression of SSTR types 1, 2A, 2B, 3, 4, and 5 was observed in 16/54 (27.6%), 40/56 (69%), 14/56 (24.1%), 9/56 (15.5%), 0/58, and 2/55 (3.4%) cases, respectively. Except for SSTR5, all SSTRs showed a tendency toward decreased expression in well- to poorly differentiated NECs. We believe that these findings indicate important implications for the future of SST analog therapy.
KW - Lung
KW - Neuroendocrine carcinoma
KW - Somatostatin receptor
UR - http://www.scopus.com/inward/record.url?scp=84864095133&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864095133&partnerID=8YFLogxK
U2 - 10.1016/j.prp.2012.05.014
DO - 10.1016/j.prp.2012.05.014
M3 - Article
C2 - 22770972
AN - SCOPUS:84864095133
SN - 0344-0338
VL - 208
SP - 470
EP - 474
JO - Pathology Research and Practice
JF - Pathology Research and Practice
IS - 8
ER -